A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Inclusion Criteria
- History of histologically documented multiple myeloma with relapsed or resistant
disease
- Pregnant or nursing women may not participate. Women of childbearing potential must
have a negative pregnancy documented within one week of registration. Women of
reproductive potential may not participate unless they have agreed to use an
effective contraceptive method.
- Signed written informed consent and willingness to meet follow-up schedule and study
procedure obligations
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Robert Knight, MD
Investigator Role:
Study Director
Investigator Affiliation:
Celgene Corporation
Authority:
United States: Food and Drug Administration
Study ID:
CC-5013-MM-008
NCT ID:
NCT00051116
Start Date:
May 2002
Completion Date:
October 2006
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Revimid
- CC5013
- CC-5013
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|---|
| Myeloma Institute University of Arkansas for Medical Sciences | Little Rock, Arkansas 72205 |
